Quetiapine as treatment for dopaminergic-induced dyskinesias in Parkinson's disease [2]

Movement Disorders

Volumn 18, Issue 10, 2003, Pages 1208-1209

  Baron, Mark S ^a   Dalton, W Brian ^b  

^a HUNTER HOLMES MCGUIRE VA MEDICAL CENTER   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; QUETIAPINE;

ADULT; AGED; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSKINESIA; FOLLOW UP; HUMAN; LETTER; MEDICAL RECORD; MOTOR PERFORMANCE; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RATING SCALE; RETROSPECTIVE STUDY; SOMNOLENCE; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 0242288088     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.10551     Document Type: Letter

References (14)

1. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995;56:556-559.
2. Meco G, Alessandri A, Giustini P, Bonifati V. Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study. Mov Disord 1997;12:610-612.
3. Ellis T, Cudkowicz ME, Sexton PM, Growdon JH. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2000;12:364-369.
4. Molho ES, Factor SA. Worsening of motor features of parkinsonism with olanzapine. Mov Disord 1999;14:1014-1016.
5. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000;55:789-794.
6. Breier A, Sutton VK, Feldman PD, Kadam DL, Ferchland I, Wright P, Friedman JH. Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease. Biol Psychiatry 2002;52:438-445.
7. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug induced psychosis in Parkinson's disease. Mov Disord 1999;14:484-487.
8. Dewey RB, O'Suilleabhain PE. Treatment of drug-induced psychosis with quetiapine and clozapine in Parkinson's disease. Neurology 2000;55:1753-1754.
9. Fernandez HH, Lannon MC, Friedman JH, Abbott BP. Clozapine replacement by quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 2000;15:579-586.
10. Targum SD, Abbott JL. Efficacy of quetiapine in Parkinson's patients with psychosis. J Clin Psychopharmacol 2000;20:54-60.
11. Reddy S, Factor SA, Molho ES, Feutsel PH. The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 2002; 17:676-681.
12. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
13. Oh JD, Bibbiani F, Chase, TN. Quetiapine attenuates levodopa-induced motor complications in rodents and primate parkinsonian models. Exp Neurol 2002;177:557-564.
14. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors: implications for atypical antipsychotic action. J Psychiatry Neurosci 2000;25:161-166.